IL-1β is considered a classic activator and mediator of inflammation, its deregulation has been implicated in a range of autoimmune diseases and strategies abolishing IL-1β signaling have proven efficient in treatment of many of these conditions [55,56,57]. The gene discussed is IL1B; the disease is autoimmune disease.